S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged

Scilex (SCLX) Competitors

$0.90
0.00 (-0.24%)
(As of 04/19/2024 08:51 PM ET)

SCLX vs. VACC, ATOS, CDXS, OGI, PROF, MASS, DRTS, AKYA, PSTX, and ME

Should you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Vaccitech (VACC), Atossa Therapeutics (ATOS), Codexis (CDXS), Organigram (OGI), Profound Medical (PROF), 908 Devices (MASS), Alpha Tau Medical (DRTS), Akoya Biosciences (AKYA), Poseida Therapeutics (PSTX), and 23andMe (ME). These companies are all part of the "medical" sector.

Scilex vs.

Vaccitech (NASDAQ:VACC) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk.

Vaccitech presently has a consensus price target of $7.63, suggesting a potential upside of 203.78%. Scilex has a consensus price target of $8.00, suggesting a potential upside of 791.07%. Given Vaccitech's stronger consensus rating and higher probable upside, analysts plainly believe Scilex is more favorable than Vaccitech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaccitech
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Scilex
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Vaccitech and Vaccitech both had 2 articles in the media. Scilex's average media sentiment score of 0.41 beat Vaccitech's score of 0.00 indicating that Vaccitech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaccitech
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Scilex
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Vaccitech received 14 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 70.83% of users gave Vaccitech an outperform vote.

CompanyUnderperformOutperform
VaccitechOutperform Votes
17
70.83%
Underperform Votes
7
29.17%
ScilexOutperform Votes
3
100.00%
Underperform Votes
No Votes

Scilex has a net margin of -244.60% compared to Scilex's net margin of -409.18%. Vaccitech's return on equity of 0.00% beat Scilex's return on equity.

Company Net Margins Return on Equity Return on Assets
Vaccitech-409.18% -23.41% -20.85%
Scilex -244.60%N/A -112.17%

Vaccitech has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500. Comparatively, Scilex has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Vaccitech has higher earnings, but lower revenue than Scilex. Vaccitech is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccitech$13.42M7.21$5.34M-$1.43-1.76
Scilex$46.74M3.19-$114.33M-$1.29-0.70

26.1% of Vaccitech shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 6.0% of Vaccitech shares are held by company insiders. Comparatively, 8.7% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Scilex beats Vaccitech on 12 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLX vs. The Competition

MetricScilexBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$149.21M$2.60B$4.88B$7.32B
Dividend YieldN/A2.30%2.93%3.97%
P/E Ratio-0.7042.99227.3620.05
Price / Sales3.19303.162,470.9681.86
Price / CashN/A139.9547.7734.38
Price / Book-0.823.714.574.15
Net Income-$114.33M-$45.59M$104.43M$214.00M
7 Day Performance-32.50%-8.73%-4.52%-3.51%
1 Month Performance-35.87%-13.05%-6.83%-6.05%
1 Year Performance-91.26%1.62%6.60%3.98%

Scilex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VACC
Vaccitech
0.8634 of 5 stars
$2.53
-4.2%
$7.63
+201.4%
+0.4%$192.74M$13.42M-1.7733Gap Up
ATOS
Atossa Therapeutics
1.1358 of 5 stars
$1.54
-9.9%
$4.50
+192.2%
+95.7%$192.96MN/A-6.4211Gap Down
CDXS
Codexis
2.9997 of 5 stars
$2.73
+1.5%
$6.80
+149.1%
-34.2%$191.92M$70.14M-2.46174
OGI
Organigram
0.4089 of 5 stars
$1.88
flat
N/A-5.5%$194.02M$120.01M-2.35984Gap Down
PROF
Profound Medical
1.6015 of 5 stars
$7.81
-1.1%
$14.58
+86.7%
-35.9%$190.80M$7.20M-5.79131Gap Down
MASS
908 Devices
1.973 of 5 stars
$5.79
flat
$14.00
+141.8%
-28.9%$190.55M$50.23M-5.12230Gap Down
DRTS
Alpha Tau Medical
1.945 of 5 stars
$2.73
-1.8%
$12.00
+338.9%
-10.2%$190.48MN/A-6.51121Positive News
High Trading Volume
AKYA
Akoya Biosciences
2.981 of 5 stars
$3.98
-0.7%
$9.07
+127.9%
-47.9%$195.58M$96.63M-2.69330Positive News
PSTX
Poseida Therapeutics
2.9899 of 5 stars
$2.03
-16.5%
$14.67
+622.5%
-29.1%$195.88M$64.70M-1.46330Gap Down
High Trading Volume
ME
23andMe
0.1731 of 5 stars
$0.39
-2.5%
$1.75
+348.6%
-76.9%$188.39M$299.49M-0.35769Gap Up

Related Companies and Tools

This page (NASDAQ:SCLX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners